Literature DB >> 1586818

Joint and limb symptoms in children after immunisation with measles, mumps, and rubella vaccine.

C M Benjamin1, G C Chew, A J Silman.   

Abstract

OBJECTIVE: To assess whether the combined measles, mumps, and rubella vaccine increases the incidence of joint and limb symptoms in young children.
DESIGN: Comparison of six week recalled incidence of symptoms in two groups of children: children who had been immunised at the start of the six weeks, and children eligible for immunisation but who had not received it.
SETTING: South Manchester Health Authority.
SUBJECTS: 2658 children immunised during July 1989-February 1990 and 2359 not yet immunised. Questionnaires were returned for 1846 immunised children and 1075 not immunised. MAIN OUTCOME MEASURE: Recalled rate of joint and limb episodes determined by postal questionnaire and later by clinical follow up.
RESULTS: Compared with non-immunised children the immunised group had an increased incidence of new episodes (relative risk 1.6 (95% confidence interval (1.2 to 2.1)) and first ever episodes, though this was not significant (1.7 (0.3 to 3.5)). The risk of first episodes was increased in girls (3.5 (1.1 to 12.2)) but not in boys (1.0 (0.4 to 2.6)). Similarly, an increased risk was seen in children aged under 5 (12.0 (1.6 to 92.3)) but not in older children (0.7 (0.3 to 1.5)). Most episodes were mild and self limiting, but three immunised children required hospital referral.
CONCLUSION: Measles, mumps, and rubella vaccine is associated with an increased risk of episodes of joint and limb symptoms, especially in girls and children under 5. The risk of frank arthritis is substantially less than after wild rubella infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1586818      PMCID: PMC1881909          DOI: 10.1136/bmj.304.6834.1075

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  9 in total

1.  Rubella, 1962.

Authors:  J Fry; J B Dillane; L Fry
Journal:  Br Med J       Date:  1962-09-29

2.  Mumps arthritis.

Authors:  R LASS; E SHEPHARD
Journal:  Br Med J       Date:  1961-12-16

3.  Surveillance of symptoms following MMR vaccine in children.

Authors:  C Miller; E Miller; K Rowe; C Bowie; M Judd; D Walker
Journal:  Practitioner       Date:  1989-01

4.  Joint complications associated with derivatives of HPV-77 rubella virus vaccine.

Authors:  S L Spruance; C B Smith
Journal:  Am J Dis Child       Date:  1971-08

5.  Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins.

Authors:  H Peltola; O P Heinonen
Journal:  Lancet       Date:  1986-04-26       Impact factor: 79.321

6.  Rubella synovitis in a one-year-old patient.

Authors:  H M Hildebrandt; H F Maassab
Journal:  N Engl J Med       Date:  1966-06-23       Impact factor: 91.245

7.  Evaluation of Wistar RA27/3 rubella virus vaccine in children.

Authors:  H H Balfour; C L Balfour; C K Edelman; P A Rierson
Journal:  Am J Dis Child       Date:  1976-10

8.  Rubella-associated arthritis. I. Comparative study of joint manifestations associated with natural rubella infection and RA 27/3 rubella immunisation.

Authors:  A J Tingle; M Allen; R E Petty; G D Kettyls; J K Chantler
Journal:  Ann Rheum Dis       Date:  1986-02       Impact factor: 19.103

9.  Some current issues relating to rubella vaccine.

Authors:  S R Preblud
Journal:  JAMA       Date:  1985-07-12       Impact factor: 56.272

  9 in total
  20 in total

1.  No evidence of an association between MMR vaccine and gait disturbance.

Authors:  E Miller; N Andrews; A Grant; J Stowe; B Taylor
Journal:  Arch Dis Child       Date:  2005-03       Impact factor: 3.791

Review 2.  Adversomics: a new paradigm for vaccine safety and design.

Authors:  Jennifer A Whitaker; Inna G Ovsyannikova; Gregory A Poland
Journal:  Expert Rev Vaccines       Date:  2015-05-02       Impact factor: 5.217

3.  Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial.

Authors:  Tracy Pondo; Charles E Rose; Stacey W Martin; Wendy A Keitel; Harry L Keyserling; Janiine Babcock; Scott Parker; Robert M Jacobson; Gregory A Poland; Michael M McNeil
Journal:  Vaccine       Date:  2014-04-24       Impact factor: 3.641

Review 4.  Sex-based differences in immune function and responses to vaccination.

Authors:  Sabra L Klein; Ian Marriott; Eleanor N Fish
Journal:  Trans R Soc Trop Med Hyg       Date:  2015-01       Impact factor: 2.184

5.  Revaccination against measles and rubella.

Authors:  F T Cutts
Journal:  BMJ       Date:  1996-03-09

6.  Can immunisation trigger rheumatoid arthritis?

Authors:  D P Symmons; K Chakravarty
Journal:  Ann Rheum Dis       Date:  1993-12       Impact factor: 19.103

7.  Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease.

Authors:  Zuzana Zelinkova; Evelien Bultman; Lauran Vogelaar; Cheima Bouziane; Ernst J Kuipers; C Janneke van der Woude
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

8.  Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis.

Authors:  Marloes W Heijstek; Gecilmara C S Pileggi; Evelien Zonneveld-Huijssoon; Wineke Armbrust; Esther P A H Hoppenreijs; Cuno S P M Uiterwaal; Wietse Kuis; Nico M Wulffraat
Journal:  Ann Rheum Dis       Date:  2007-02-06       Impact factor: 19.103

9.  Arthritis after mumps and measles vaccination.

Authors:  M Nussinovitch; L Harel; I Varsano
Journal:  Arch Dis Child       Date:  1995-04       Impact factor: 3.791

10.  Knowledge synthesis of benefits and adverse effects of measles vaccination: the Lasbela balance sheet.

Authors:  Robert J Ledogar; John Fleming; Neil Andersson
Journal:  BMC Int Health Hum Rights       Date:  2009-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.